Biogen Inc. (0R1B.L)
USD 150.06
(-0.94%)
USD 150.06
(-0.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.16 Billion USD | -61.89% |
| 2022 | 3.04 Billion USD | 95.8% |
| 2021 | 1.55 Billion USD | -61.1% |
| 2020 | 4 Billion USD | -32.06% |
| 2019 | 5.88 Billion USD | 32.9% |
| 2018 | 4.43 Billion USD | 74.5% |
| 2017 | 2.53 Billion USD | -31.43% |
| 2016 | 3.7 Billion USD | 4.39% |
| 2015 | 3.54 Billion USD | 20.86% |
| 2014 | 2.93 Billion USD | 57.59% |
| 2013 | 1.86 Billion USD | 34.95% |
| 2012 | 1.38 Billion USD | 11.8% |
| 2011 | 1.23 Billion USD | 22.8% |
| 2010 | 1 Billion USD | 3.62% |
| 2009 | 970.13 Million USD | 23.87% |
| 2008 | 783.16 Million USD | 22.72% |
| 2007 | 638.17 Million USD | 193.4% |
| 2006 | 217.51 Million USD | 35.34% |
| 2005 | 160.71 Million USD | 540.64% |
| 2004 | 25.08 Million USD | 102.87% |
| 2003 | -875.09 Million USD | -539.42% |
| 2002 | 199.14 Million USD | -26.97% |
| 2001 | 272.68 Million USD | -18.25% |
| 2000 | 333.57 Million USD | 51.32% |
| 1999 | 220.45 Million USD | 58.94% |
| 1998 | 138.69 Million USD | 55.55% |
| 1997 | 89.16 Million USD | 120.0% |
| 1996 | 40.53 Million USD | 616.08% |
| 1995 | 5.66 Million USD | 215.58% |
| 1994 | -4.89 Million USD | -115.11% |
| 1993 | 32.4 Million USD | -15.4% |
| 1992 | 38.3 Million USD | 431.94% |
| 1991 | 7.2 Million USD | -6.49% |
| 1990 | 7.7 Million USD | 140.63% |
| 1989 | 3.2 Million USD | 366.67% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 393.4 Million USD | 57.55% |
| 2024 Q2 | 583.6 Million USD | 48.35% |
| 2024 Q3 | 388.5 Million USD | -33.43% |
| 2023 Q4 | 249.7 Million USD | 466.67% |
| 2023 Q3 | -68.1 Million USD | -111.51% |
| 2023 Q1 | 387.9 Million USD | -29.52% |
| 2023 FY | 1.16 Billion USD | -61.89% |
| 2023 Q2 | 591.6 Million USD | 52.51% |
| 2022 Q2 | 1.05 Billion USD | 377.01% |
| 2022 FY | 3.04 Billion USD | 95.8% |
| 2022 Q4 | 550.4 Million USD | -51.49% |
| 2022 Q3 | 1.13 Billion USD | 7.25% |
| 2022 Q1 | 221.8 Million USD | -39.76% |
| 2021 Q2 | 448.5 Million USD | 9.34% |
| 2021 FY | 1.55 Billion USD | -61.1% |
| 2021 Q3 | 329.2 Million USD | -26.6% |
| 2021 Q4 | 368.2 Million USD | 11.85% |
| 2021 Q1 | 410.2 Million USD | 14.61% |
| 2020 FY | 4 Billion USD | -32.06% |
| 2020 Q3 | 701.5 Million USD | -54.51% |
| 2020 Q1 | 1.39 Billion USD | -2.82% |
| 2020 Q2 | 1.54 Billion USD | 10.22% |
| 2020 Q4 | 357.9 Million USD | -48.98% |
| 2019 Q3 | 1.54 Billion USD | 3.47% |
| 2019 Q2 | 1.49 Billion USD | 6.05% |
| 2019 FY | 5.88 Billion USD | 32.9% |
| 2019 Q1 | 1.4 Billion USD | 48.8% |
| 2019 Q4 | 1.43 Billion USD | -6.87% |
| 2018 FY | 4.43 Billion USD | 74.5% |
| 2018 Q3 | 1.44 Billion USD | 66.67% |
| 2018 Q2 | 866.6 Million USD | -26.11% |
| 2018 Q1 | 1.17 Billion USD | 494.38% |
| 2018 Q4 | 946.8 Million USD | -34.45% |
| 2017 Q3 | 1.22 Billion USD | 42.11% |
| 2017 Q1 | 747.6 Million USD | 15.16% |
| 2017 Q4 | -297.4 Million USD | -124.26% |
| 2017 Q2 | 862.8 Million USD | 15.41% |
| 2017 FY | 2.53 Billion USD | -31.43% |
| 2016 Q4 | 649.2 Million USD | -37.15% |
| 2016 Q1 | 970.9 Million USD | 16.76% |
| 2016 Q2 | 1.04 Billion USD | 8.13% |
| 2016 Q3 | 1.03 Billion USD | -1.61% |
| 2016 FY | 3.7 Billion USD | 4.39% |
| 2015 FY | 3.54 Billion USD | 20.86% |
| 2015 Q4 | 831.56 Million USD | -13.88% |
| 2015 Q3 | 965.6 Million USD | 4.13% |
| 2015 Q2 | 927.3 Million USD | 12.74% |
| 2015 Q1 | 822.5 Million USD | -6.9% |
| 2014 Q1 | 479.95 Million USD | 4.95% |
| 2014 Q3 | 856.85 Million USD | 19.92% |
| 2014 FY | 2.93 Billion USD | 57.59% |
| 2014 Q4 | 883.46 Million USD | 3.11% |
| 2014 Q2 | 714.5 Million USD | 48.87% |
| 2013 Q3 | 487.61 Million USD | -0.62% |
| 2013 FY | 1.86 Billion USD | 34.95% |
| 2013 Q1 | 426.74 Million USD | 46.08% |
| 2013 Q2 | 490.67 Million USD | 14.98% |
| 2013 Q4 | 457.3 Million USD | -6.22% |
| 2012 Q1 | 302.66 Million USD | 0.81% |
| 2012 Q3 | 398.4 Million USD | 2.99% |
| 2012 Q4 | 292.12 Million USD | -26.67% |
| 2012 Q2 | 386.84 Million USD | 27.81% |
| 2012 FY | 1.38 Billion USD | 11.8% |
| 2011 FY | 1.23 Billion USD | 22.8% |
| 2011 Q4 | 300.23 Million USD | -14.66% |
| 2011 Q3 | 351.82 Million USD | 22.15% |
| 2011 Q2 | 288.03 Million USD | -1.96% |
| 2011 Q1 | 293.8 Million USD | 22.28% |
| 2010 Q1 | 217 Million USD | -29.0% |
| 2010 FY | 1 Billion USD | 3.62% |
| 2010 Q4 | 240.27 Million USD | -5.45% |
| 2010 Q3 | 254.11 Million USD | -13.4% |
| 2010 Q2 | 293.43 Million USD | 35.22% |
| 2009 Q4 | 305.63 Million USD | 10.07% |
| 2009 Q3 | 277.66 Million USD | 94.38% |
| 2009 FY | 970.13 Million USD | 23.87% |
| 2009 Q1 | 243.98 Million USD | 18.07% |
| 2009 Q2 | 142.84 Million USD | -41.45% |
| 2008 FY | 783.16 Million USD | 22.72% |
| 2008 Q1 | 163.39 Million USD | -18.77% |
| 2008 Q2 | 206.32 Million USD | 26.27% |
| 2008 Q3 | 206.78 Million USD | 0.22% |
| 2008 Q4 | 206.65 Million USD | -0.06% |
| 2007 FY | 638.17 Million USD | 193.4% |
| 2007 Q2 | 185.94 Million USD | 41.18% |
| 2007 Q3 | 119.58 Million USD | -35.69% |
| 2007 Q4 | 201.15 Million USD | 68.21% |
| 2007 Q1 | 131.7 Million USD | 21.32% |
| 2006 Q3 | 156.79 Million USD | 191.9% |
| 2006 Q4 | 108.55 Million USD | -30.77% |
| 2006 Q2 | -170.61 Million USD | -238.95% |
| 2006 Q1 | 122.79 Million USD | 121.0% |
| 2006 FY | 217.51 Million USD | 35.34% |
| 2005 Q4 | 55.56 Million USD | 104.69% |
| 2005 FY | 160.71 Million USD | 540.64% |
| 2005 Q2 | 34.45 Million USD | -20.6% |
| 2005 Q1 | 43.39 Million USD | 51.26% |
| 2005 Q3 | 27.14 Million USD | -21.21% |
| 2004 Q3 | 36.71 Million USD | 4344.79% |
| 2004 Q4 | 28.68 Million USD | -21.86% |
| 2004 FY | 25.08 Million USD | 102.87% |
| 2004 Q1 | -41.19 Million USD | 96.08% |
| 2004 Q2 | 826 Thousand USD | 102.0% |
| 2003 Q1 | 63.53 Million USD | 53.37% |
| 2003 Q3 | 44.87 Million USD | -22.46% |
| 2003 Q4 | -1.05 Billion USD | -2443.74% |
| 2003 Q2 | 57.87 Million USD | -8.91% |
| 2003 FY | -875.09 Million USD | -539.42% |
| 2002 Q3 | 42.2 Million USD | -2.69% |
| 2002 Q4 | 41.42 Million USD | -1.86% |
| 2002 Q2 | 43.37 Million USD | -39.87% |
| 2002 Q1 | 72.14 Million USD | 22.51% |
| 2002 FY | 199.14 Million USD | -26.97% |
| 2001 Q2 | 71.85 Million USD | -0.38% |
| 2001 Q3 | 69.82 Million USD | -2.82% |
| 2001 Q4 | 58.88 Million USD | -15.67% |
| 2001 FY | 272.68 Million USD | -18.25% |
| 2001 Q1 | 72.12 Million USD | 0.49% |
| 2000 Q1 | 121.36 Million USD | 75.01% |
| 2000 Q3 | 68.38 Million USD | -5.11% |
| 2000 Q2 | 72.06 Million USD | -40.63% |
| 2000 Q4 | 71.77 Million USD | 4.96% |
| 2000 FY | 333.57 Million USD | 51.32% |
| 1999 Q1 | 45.7 Million USD | 9.08% |
| 1999 Q3 | 62 Million USD | 42.86% |
| 1999 Q4 | 69.35 Million USD | 11.85% |
| 1999 FY | 220.45 Million USD | 58.94% |
| 1999 Q2 | 43.4 Million USD | -5.03% |
| 1998 Q2 | 31.4 Million USD | 12.95% |
| 1998 Q4 | 41.89 Million USD | 11.43% |
| 1998 FY | 138.69 Million USD | 55.55% |
| 1998 Q1 | 27.8 Million USD | -12.49% |
| 1998 Q3 | 37.6 Million USD | 19.75% |
| 1997 Q3 | 20.5 Million USD | 3.02% |
| 1997 FY | 89.16 Million USD | 120.0% |
| 1997 Q1 | 17 Million USD | 106.56% |
| 1997 Q2 | 19.9 Million USD | 17.06% |
| 1997 Q4 | 31.76 Million USD | 54.96% |
| 1996 FY | 40.53 Million USD | 616.08% |
| 1996 Q4 | 8.23 Million USD | -81.75% |
| 1996 Q3 | 45.1 Million USD | 595.6% |
| 1996 Q2 | -9.1 Million USD | -145.95% |
| 1996 Q1 | -3.7 Million USD | -485.42% |
| 1995 Q3 | 1.1 Million USD | 57.14% |
| 1995 Q4 | 960 Thousand USD | -12.73% |
| 1995 FY | 5.66 Million USD | 215.58% |
| 1995 Q2 | 700 Thousand USD | -75.0% |
| 1995 Q1 | 2.8 Million USD | -71.14% |
| 1994 FY | -4.89 Million USD | -115.11% |
| 1994 Q1 | 11.2 Million USD | 166.67% |
| 1994 Q2 | 600 Thousand USD | -94.64% |
| 1994 Q3 | -26.4 Million USD | -4500.0% |
| 1994 Q4 | 9.7 Million USD | 136.75% |
| 1993 FY | 32.4 Million USD | -15.4% |
| 1993 Q2 | 5.6 Million USD | -50.44% |
| 1993 Q1 | 11.3 Million USD | -56.03% |
| 1993 Q4 | 4.2 Million USD | -62.83% |
| 1993 Q3 | 11.3 Million USD | 101.79% |
| 1992 FY | 38.3 Million USD | 431.94% |
| 1992 Q3 | 11.1 Million USD | 1485.71% |
| 1992 Q4 | 25.7 Million USD | 131.53% |
| 1992 Q2 | 700 Thousand USD | -12.5% |
| 1992 Q1 | 800 Thousand USD | -20.0% |
| 1991 FY | 7.2 Million USD | -6.49% |
| 1991 Q2 | 2.3 Million USD | -20.69% |
| 1991 Q4 | 1 Million USD | 0.0% |
| 1991 Q3 | 1 Million USD | -56.52% |
| 1991 Q1 | 2.9 Million USD | 11.54% |
| 1990 Q1 | 1.7 Million USD | 6.25% |
| 1990 Q4 | 2.6 Million USD | 44.44% |
| 1990 Q3 | 1.8 Million USD | 12.5% |
| 1990 Q2 | 1.6 Million USD | -5.88% |
| 1990 FY | 7.7 Million USD | 140.63% |
| 1989 Q2 | -200 Thousand USD | -300.0% |
| 1989 FY | 3.2 Million USD | 366.67% |
| 1989 Q1 | 100 Thousand USD | -50.0% |
| 1989 Q3 | 1.7 Million USD | 950.0% |
| 1989 Q4 | 1.6 Million USD | -5.88% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 857.804% |
| Dynavax Technologies Corporation | -6.38 Million USD | 18273.423% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -88129.483% |
| Perrigo Company plc | -12.7 Million USD | 9242.52% |
| Illumina, Inc. | -1.16 Billion USD | 200.009% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 80.632% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 361.487% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 113.445% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 14.499% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 1150.208% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 70.632% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 3012.945% |
| Waters Corporation | 642.23 Million USD | -80.791% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 550.334% |
| Evolus, Inc. | -61.68 Million USD | 1982.305% |
| Adicet Bio, Inc. | -142.65 Million USD | 913.905% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 1079.724% |
| bluebird bio, Inc. | -211.91 Million USD | 647.914% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 654.892% |
| FibroGen, Inc. | -284.23 Million USD | 508.504% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 6.363% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 2703.17% |
| Homology Medicines, Inc. | -53.74 Million USD | 2260.467% |
| Geron Corporation | -184.12 Million USD | 730.597% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 363.741% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 865.978% |
| Myriad Genetics, Inc. | -112 Million USD | 1136.696% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 1451.767% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 341.297% |
| Zoetis Inc. | 2.34 Billion USD | 50.465% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 2242.725% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -47.202% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -592.594% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 67.922% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 2851.487% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 416.993% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 520.496% |
| Verastem, Inc. | -87.36 Million USD | 1428.991% |
| Nektar Therapeutics | -276.05 Million USD | 520.603% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 585.333% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 1412.259% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 316.632% |
| OPKO Health, Inc. | -188.86 Million USD | 714.784% |
| Exelixis, Inc. | 207.76 Million USD | -458.853% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -364.998% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -993.933% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 2544.164% |
| uniQure N.V. | -308.47 Million USD | 476.396% |
| Imunon, Inc. | -19.51 Million USD | 6049.789% |
| Blueprint Medicines Corporation | -506.98 Million USD | 329.021% |
| Insmed Incorporated | -749.56 Million USD | 254.903% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -312.331% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 429.776% |
| TG Therapeutics, Inc. | 12.67 Million USD | -9062.721% |
| Incyte Corporation | 597.59 Million USD | -94.294% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 252.676% |